Increased CK2 levels and/or activity have been previously reported in AD and AD models [19, 37, 72], and CK2 has been associated with tau pathology [19, 20, 72, 97], microglia state [98, 99] and general inflammation [100-106]. This evidence concerns the gene MAPT and Alzheimer disease.